Trials / Completed
CompletedNCT02156791
Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM
Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM Administered Subcutaneously to Hay Fever Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- BioTech Tools S.A. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
gpASIT+TM product is based on highly purified allergen fragments obtained from grass pollen. The purpose of this clinical trial is to confirm the safety, clinical tolerability and immunogenicity of increasing doses of gpASIT+TM administered subcutaneously to patients with grass pollen-induced allergic rhinoconjunctivitis, and to determine the maximal tolerated dose of gpASIT+TM .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | gpASIT+TM |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2013-12-01
- Completion
- 2013-12-01
- First posted
- 2014-06-05
- Last updated
- 2014-06-06
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02156791. Inclusion in this directory is not an endorsement.